# ACT Genomics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/act-genomics-co

- Industry: Biotechnology
- Headquarters: Taipei, Taiwan - China
- Website: www.actgenomics.com
- Total disclosed funding: $13M
- Latest round: Series B (May 6, 2016)
- Investors on record: 6

## About

ACT Genomics Co., LTD. is a biotechnology firm specializing in precision medicine through advanced genomic testing solutions that enhance cancer care and treatment personalization.Founded in 2014 and headquartered in Taipei, Taiwan, ACT Genomics Co., LTD. focuses on providing genomic testing services to optimize cancer treatment. The company has engaged in five notable deals, with the most recent being a TRADE SALE on December 16, 2022, where Prenetics Global Limited acquired ACT Genomics for USD 20.00 mn. The CEO of the company is Walt Ling.ACT Genomics specializes in precision medicine via advanced genomic testing solutions aimed at improving cancer care. The company offers various genomic assays, including comprehensive and targeted panels, to identify biomarkers and genomic alterations linked to different cancers. These tests enable personalized treatment strategies by helping oncologists align patients with specific therapies and clinical trials based on their unique genetic profiles. With a client base exceeding 200 hospitals and clinics and over 700 physicians, ACT Genomics collaborates with more than 20 biopharma companies and research institutes for clinical diagnostics and research. Their products are primarily marketed in Asia, highlighting their first FDA 510(k) clearance product which underscores their commitment to patient safety and effective solutions.ACT Genomics generates revenue through B2B transactions with healthcare professionals and institutions by providing genomic testing services and consulting for cancer management. Collaborating with healthcare providers allows the company to deliver actionable insights from genomic profiling, which assists in treatment selection and patient management. Revenue streams consist of service fees for genomic tests, and potential subscription models for ongoing support and resources offered to healthcare practitioners. While specific pricing and transaction details are not publicly disclosed, the emphasis on quality and precision in their offerings positions their services as essential components of contemporary cancer care.The recent acquisition by Prenetics Global Limited is anticipated to close on or around December 30, 2022, allowing ACT Genomics to leverage genetic information across a patient's cancer journey. As part of its growth strategy, ACT Genomics may explore new products and services tailored to evolving market needs, although specific upcoming releases have not been publicly detailed. The planned integration with Prenetics aims to enhance the application of genetic data in oncology, potentially leading to further market expansion.

## Funding rounds

- Series B, May 6, 2016, $13M — TaiAn Technologies Corporation, CDIB Capital Group, President International Development Corporation, Hotung Investment Holdings, Hua Nan Venture Capital, UMC Capital

## Investors

- TaiAn Technologies Corporation (https://capitalatlas.ai/funds/taian-technologies-corporation) — Series B
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series B
- President International Development Corporation — Series B
- Hotung Investment Holdings (https://capitalatlas.ai/funds/hotung-investment-holdings) — Series B
- Hua Nan Venture Capital (https://capitalatlas.ai/funds/hua-nan-venture-capital) — Series B
- UMC Capital (https://capitalatlas.ai/funds/umc-capital) — Series B